Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Multiple Share Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of common stock purchases between January 13th and January 15th, 2025.

Summary

• EcoR1 Capital, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported several transactions involving the purchase of Zymeworks Inc. common stock.
• On January 13, 2025, 74,125 shares were purchased at a price of $13.3946 per share.
• On January 14, 2025, 54,500 shares were purchased at a price of $13.5645 per share.
• On January 15, 2025, 39,029 shares were purchased at a price of $14.0068 per share.
• These transactions increased EcoR1's total indirect beneficial ownership to 15,578,732 shares.
• The purchases were made by EcoR1 Capital Fund Qualified, L.P., a fund managed by EcoR1 Capital, LLC.
• Oleg Nodelman, the manager of EcoR1, may also be deemed to indirectly beneficially own these shares.

Sentiment

Score: 7

Explanation: The document indicates a positive sentiment as a major shareholder is increasing their stake, suggesting confidence in the company. However, it is a standard filing and does not contain any specific forward-looking statements.

Positives

• EcoR1 Capital's increased investment suggests confidence in Zymeworks Inc.'s future prospects.
• The consistent purchases over three days indicate a deliberate strategy to increase their position.

Risks

• The document does not provide any information about the reasons for the purchases, so it is difficult to assess the underlying motivation.
• The document does not provide any information about the future plans of EcoR1 Capital.

Industry Context

This filing reflects a significant investor's activity in the biotechnology sector, where strategic investments and ownership changes are common. It is not unusual for large shareholders to increase their positions in companies they believe have growth potential.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The reported transactions are typical for institutional investors adjusting their positions in response to market conditions or company-specific developments.
• Comparable companies in the biotechnology sector often see similar filings from their major shareholders.

Stakeholder Impact

• The increased ownership by EcoR1 Capital could be viewed positively by other shareholders, potentially increasing confidence in the company.
• The transactions may have a minor impact on the stock price in the short term.

Key Dates

Keywords

Zymeworks Inc., EcoR1 Capital, share purchase, beneficial ownership, common stock, Oleg Nodelman, investment